ABSTRACT
Perinatal depression affects 10% to 20% of women in the United States during pregnancy, the postpartum period, or both, but it can be difficult to recognize. Identifying and treating this problem can reduce the alarming number of suicides among depressed perinatal women and the possible adverse effects of untreated maternal depression on their child’s cognitive and behavioral development. In this review, we discuss the latest developments in screening, treatment, and prevention methods.
Footnotes
Dr. Payne has disclosed membership on advisory committees or review panels for Janssen Pharmaceuticals Inc.
Dedication: This article is dedicated to Paul and Margaret Burke.
- Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.
- Maureen Sayres Van Niel, MD⇑
- President, American Psychiatric Association Women’s Caucus; Member, Steering Committee, US Dept of HHS Women’s Preventive Services Initiative, WPSI, 2016-2019; Reproductive Psychiatrist and Private Consultant, Cambridge, MA
- Address:
Maureen Sayres Van Niel, MD, President, APA Women’s Caucus, American Psychiatric Association, 25 York Road, Waban, MA 02468; maureen.vanniel{at}gmail.com
- Jennifer L. Payne, MD
ABSTRACT
Perinatal depression affects 10% to 20% of women in the United States during pregnancy, the postpartum period, or both, but it can be difficult to recognize. Identifying and treating this problem can reduce the alarming number of suicides among depressed perinatal women and the possible adverse effects of untreated maternal depression on their child’s cognitive and behavioral development. In this review, we discuss the latest developments in screening, treatment, and prevention methods.
Footnotes
Dr. Payne has disclosed membership on advisory committees or review panels for Janssen Pharmaceuticals Inc.
Dedication: This article is dedicated to Paul and Margaret Burke.
- Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.